TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.

Tonghua Dongbao Pharmaceutical Co., Ltd.

600867

CNE000000H87

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
10.15 ^CNY	+0.30%		-2.31%	-6.28%

May. 10	Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake	MT
May. 08	JHM Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Tonghua Dongbao Pharmaceutical Co., Ltd.	CI

Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.

September 26, 2022

From July 1, 2022 to September 24, 2022, the company has repurchased 14,499,918 shares, representing 0.73% for CNY 131.9 million. With this, the company has completed the repurchase of 15,699,918 shares, representing 0.78% for CNY 143.57 million under the buyback announced on June 15, 2022.

Latest news about Tonghua Dongbao Pharmaceutical Co., Ltd.

Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake	May. 10	MT
JHM Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Tonghua Dongbao Pharmaceutical Co., Ltd.	May. 07	CI
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024	Apr. 29	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Dongbao Pharma's 2023 Profit Drops 26%	Mar. 29	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 29	CI
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint	Jan. 17	MT
Dongbao Pharmaceutical's Unit Gets Nod to Trial Diabetes Drug	Dec. 27	MT
Dongbao Pharmaceutical Unit Gets Nod to Trial Diabetes Drug	Dec. 12	MT
Tonghua Dongbao Pharma Unit Enrolls First Subject for Clinical Trial of Diabetes Drug	Dec. 06	MT
Tonghua Dongbao Pharma Registers Diabetes Drug	Dec. 05	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Tonghua Dongbao Pharmaceutical's Insulin Injection Shows Positive Results in German Trial	23-10-24	MT
Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao	23-10-23	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	23-09-21	CI
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to S&P Global BMI Index	23-09-18	CI
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to FTSE All-World Index	23-09-18	CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Tonghua Dongbao Pharmaceutical Enrolls First Subject for Phase II Trial of Gout Drug; Shares Rose 4%	23-02-08	MT
Tonghua Dongbao Pharma’s Net Profit Jumps 21% Despite Revenue Drop	23-02-07	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-06	CI
Tonghua Dongbao Pharma Wins Nod to Trial Drug Against Uric Acid, Gout	22-12-23	MT
Tonghua Dongbao Gets Regulatory Approval For Two Insulin Injections	22-11-16	MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-23	CI

Chart Tonghua Dongbao Pharmaceutical Co., Ltd.

Duration

Period

Chart Tonghua Dongbao Pharmaceutical Co., Ltd.

More charts

Company Profile

TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tonghua Dongbao Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.15 CNY

Average target price

14.36 CNY

Spread / Average Target

+41.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.	-6.28%	2.76B
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.69%	32.81B
UCB	+52.41%	25B
BIOMARIN PHARMACEUTICAL INC.	-17.49%	15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.98B
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B

Biopharmaceuticals

Tonghua Dongbao Pharmaceutical Co., Ltd.

Equities

600867

CNE000000H87

Pharmaceuticals

Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.

EPS Revisions